This study describes the discovery and characterization of a highly-potent BK polyomavirus-neutralizing antibody, identified from a kidney transplant recipient who displayed rapid clearance of high-level BKPyV-DNAemia.
This poster highlights a scoping literature review which aimed to synthesize the current evidence on burden of BKV infection and BKVN in kidney transplant recipients, with a focus on identifying patient-centered research and outcomes.
BK virus (BKV) is a common latent virus that can reactivate in 8 kidney transplant recipients due to immunosuppressive therapy, potentially 9 leading to graft dysfunction or loss.
This paper highlights the Phase I clinical data, including safety, tolerability, and pharmacokinetics, for potravitug, a highly potent human monoclonal antibody targeting BK polyomavirus.
Ipsen acquired Memo Therapeutics’ clinical-stage program potravitug, a first-in-class BK polyomavirus monoclonal antibody. Phase II SAFE KIDNEY II trial results support a planned Phase II/III trial.
